SGLT2 Inhibitors for Heart Failure Treatment
Author Information
Author(s): Chen Ya-ru, Zhu Fang-yuan, Zhou Rong
Primary Institution: The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
Hypothesis
Can SGLT2 inhibitors improve heart failure outcomes through non-hypoglycemic mechanisms?
Conclusion
SGLT2 inhibitors can improve cardiac function in heart failure patients by reducing volume load, regulating metabolism, and mitigating inflammation.
Supporting Evidence
- SGLT2 inhibitors prevent cardiovascular events and reduce the risk of death and hospital admission from heart failure.
- Patients without type 2 diabetes also benefit from SGLT2 inhibitors similarly to those with diabetes.
- SGLT2 inhibitors improve cardiac function through mechanisms like reducing inflammation and oxidative stress.
Takeaway
SGLT2 inhibitors help hearts work better by getting rid of extra fluid and helping the heart use energy more efficiently.
Methodology
This review analyzes existing studies on the effects of SGLT2 inhibitors on heart failure.
Limitations
Most evidence is based on animal studies and the clinical studies have small and limited diverse populations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website